Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Net Income towards Common Stockholders (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Net Income towards Common Stockholders for 6 consecutive years, with -$23.0 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 31.5% to -$23.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$50.2 million through Dec 2025, up 17.57% year-over-year, with the annual reading at -$50.2 million for FY2025, 17.57% up from the prior year.
  • Net Income towards Common Stockholders hit -$23.0 million in Q4 2025 for Insight Molecular Diagnostics, down from -$10.9 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $2397.0 in Q1 2023 to a low of -$45.2 million in Q4 2022.
  • Historically, Net Income towards Common Stockholders has averaged -$13.9 million across 5 years, with a median of -$9.7 million in 2025.
  • Biggest five-year swings in Net Income towards Common Stockholders: skyrocketed 100.02% in 2023 and later tumbled 389545.14% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$35.9 million in 2021, then fell by 25.97% to -$45.2 million in 2022, then skyrocketed by 85.21% to -$6.7 million in 2023, then plummeted by 401.14% to -$33.5 million in 2024, then soared by 31.5% to -$23.0 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for IMDX at -$23.0 million in Q4 2025, -$10.9 million in Q3 2025, and -$9.7 million in Q2 2025.